IMMUNOMIND

ImmunoMind uses AI and multi-omics to predict the efficacy of immunotherapies and stratify patients... Early assessment of CAR-T cell population essential characteristics helps improve the probability of success in later drug development stages. ImmunoMind's platform automatically evaluates CAR-T cells' activation, proliferation, cytotoxicity, senescence, and exhaustion. The platform simultaneously compares the characteristics of several CAR-T products and helps companies choose the best candidate... Apply novel strategies to improve the CAR-T product's efficacy by exhaustion estimation.

Also known as: ImmunoMind Inc., ImmunoMind Sp. z o.o.

Primary location: Berkeley United States